viral
test
result
includ
clinic
site
could
perform
prior
picu
admiss
well
addit
studi
test
done
marshfield
clinic
research
foundat
marshfield
wi
influenza
viral
test
method
previous
report
virus
test
includ
respiratori
syncyti
viru
human
metapneumoviru
human
rhinoviru
parainfluenza
viru
influenza
b
includ
subtyp
coronaviru
adenoviru
bacteri
coinfect
defin
diagnosi
clinic
site
microbiolog
identif
pathogen
within
hour
prior
picu
admiss
rule
hospitalacquir
infect
cultur
come
steril
site
endotrach
bronchoscop
specimen
bloodstream
pleural
fluid
posit
test
mrsa
colon
screen
alon
insuffici
determin
bacteri
coinfect
race
ethnic
captur
parent
interview
pediatr
risk
mortal
iii
acut
physiolog
prism
iii
score
measur
sever
ill
within
hour
picu
admiss
invas
mechan
ventil
via
ett
acut
lung
injuri
ali
acut
respiratori
distress
syndrom
ard
acut
onset
respiratori
distress
hypoxia
ratio
ali
ard
bilater
infiltr
chest
radiograph
evid
left
heart
failur
shock
requir
vasopressor
support
use
dopamin
infus
epinephrin
norepinephrin
phenylephrin
infus
maintain
blood
pressur
mortal
death
index
hospit
site
investig
collect
data
baselin
demograph
inform
ill
durat
present
symptom
initi
picu
admiss
find
select
clinic
event
outcom
hospit
picu
discharg
data
enter
redcap
electron
case
report
form
host
secur
server
boston
children
hospit
record
baselin
valu
laboratori
result
vital
sign
vasoactiveinotrop
dose
chest
radiograph
result
oxygen
first
record
valu
picu
valu
unavail
valu
closest
admiss
transport
emerg
depart
referr
hospit
use
data
collect
close
possibl
data
consid
miss
valu
avail
final
outcom
survivaldeath
track
initi
picu
discharg
date
patient
hospit
discharg
patient
transfer
ward
data
antibiot
given
first
hour
picu
admiss
prior
picu
admiss
collect
prospect
children
coinfect
site
collect
inform
time
antibiot
prior
picu
admiss
well
vancomycin
trough
level
vancomycin
dose
antibiot
suscept
test
result
retrospect
sampl
blood
endotrach
aspir
intub
taken
enrol
within
hour
picu
admiss
day
later
still
picu
ett
aspir
kept
ice
centrifug
ett
supernat
aliquot
store
concentr
cytokin
measur
duplic
univers
minnesota
cytokin
refer
laboratori
use
standard
enzymelink
immunosorb
assay
well
beadbas
luminex
multiplex
assay
luminex
platform
austin
tx
describ
detail
recent
public
statist
analysi
perform
use
sa
softwar
version
cari
nc
categor
variabl
compar
use
fisher
exact
test
mannwhitney
u
test
continu
variabl
analyz
use
spearman
correl
kruskalw
test
dunn
test
posthoc
analys
logist
regress
adjust
age
prism
iii
score
use
confirm
associ
mortal
earli
vancomycin
monotherapi
vs
addit
earli
antimrsa
antibiot
group
choic
earli
within
first
hour
picu
admiss
antimrsa
antibiot
administr
children
coinfect
vari
one
child
die
receiv
earli
clindamycin
monotherapi
earli
vancomycin
given
patient
n
figur
show
whether
addit
earli
antimrsa
antibiot
receiv
patient
stratifi
children
hospit
surviv
although
n
receiv
vancomycin
monotherapi
n
receiv
addit
therapi
commonli
clindamycin
children
receiv
third
earli
antimrsa
antibiot
receiv
ceftarolin
receiv
linezolid
receiv
ceftarolin
plu
vancomycin
age
gender
prism
iii
score
type
influenza
infect
influenza
vaccin
significantli
differ
earli
vancomycin
monotherapi
addit
earli
antimrsa
antibiot
group
see
supplementari
tabl
mortal
n
receiv
earli
vancomycin
monotherapi
compar
n
receiv
vancomycin
second
antimrsa
agent
within
first
hour
rr
ci
p
estim
number
need
treat
antimrsa
agent
prevent
death
would
ci
find
remain
signific
p
adjust
ill
sever
first
hour
prism
iii
score
age
major
children
surviv
die
receiv
extracorpor
life
support
children
data
avail
time
present
receiv
vancomycin
monotherapi
addit
antimrsa
therapi
report
median
time
symptom
onset
present
day
iqr
vs
day
iqr
respect
p
even
imput
percentil
respect
time
present
miss
data
day
death
day
survivor
time
present
would
reach
statist
signific
group
children
vancomycinonli
group
miss
data
survivor
test
mrsa
isol
suscept
clindamycin
n
mrsa
isol
test
minimum
inhibitori
concentr
mic
test
mrsa
isol
vancomycin
children
report
abl
obtain
first
vancomycin
trough
level
children
mrsa
receiv
vancomycin
first
hour
exclud
patient
acut
renal
failur
admiss
whose
vancomycin
dose
requir
adjust
shown
figur
initi
vancomycin
trough
level
vancomycin
dose
associ
vancomycin
trough
level
figur
children
influenzarel
acut
respiratori
failur
multicent
picu
cohort
mrsa
coinfect
sever
ill
children
coinfect
bacteria
bacteri
coinfect
time
like
die
antimrsa
antibiot
given
within
hour
picu
admiss
associ
hospit
outcom
children
receiv
earli
vancomycin
sole
antimrsa
agent
time
higher
risk
mortal
children
receiv
earli
vancomycin
plu
earli
addit
anoth
antimrsa
agent
choic
antimicrobi
therapi
mostli
empir
bacteri
diagnosi
usual
take
longer
hour
factor
distinguish
children
major
adolesc
previous
healthi
usual
develop
leukopenia
first
picu
day
frequent
neutropenia
despit
higher
gcsf
serum
level
often
cannul
ecmo
support
earli
recognit
patient
profil
could
guid
choic
empir
therapi
difficulti
reach
therapeut
level
vancomycin
pediatr
patient
good
renal
clearanc
common
consist
improv
addit
vancomycin
load
dose
areaunderthecurv
auc
mic
ratio
posit
potenti
better
predictor
vancomycin
efficaci
vancomycin
trough
level
howev
clinic
outcom
report
improv
even
adequ
auc
mic
earli
invas
mrsa
infect
investig
systemat
review
avail
studi
conclud
vancomycin
poorli
penetr
lung
tissu
compar
simultan
plasma
level
concentr
lung
epitheli
line
fluid
rang
concentr
whole
homogen
lung
tissu
rang
mrsa
suscept
clindamycin
second
commonli
prescrib
antimrsa
agent
near
univers
cohort
unfortun
suscept
aureu
clindamycin
may
declin
us
children
via
mechan
protein
synthesi
inhibit
present
vancomycin
clindamycin
antitoxin
effect
vitro
although
data
vitro
model
also
suggest
antagon
exist
vancomycin
combin
clindamycin
linezolid
poor
agreement
anim
human
model
antibiot
antagon
synergi
treat
mrsa
ultim
choic
second
antimrsa
agent
influenc
local
mrsa
antibiogram
ceftarolin
clinic
approv
mrsacap
skin
soft
tissu
infect
use
surviv
patient
adjunct
antibiot
vancomycin
rigor
pharmacokinet
outcom
data
ceftarolin
treatment
intub
children
mrsa
pneumonia
lack
strength
studi
includ
prospect
enrol
rigor
data
collect
sensit
influenza
test
clinic
care
control
reveal
high
practic
variabl
across
center
empir
choic
dose
time
vancomycin
use
addit
antimrsa
antibiot
studi
numer
limit
design
observ
cohort
mrsa
patient
rel
small
includ
mrsacoinfect
patient
mrsarel
death
despit
involv
larg
picu
year
children
sever
comorbid
health
condit
predispos
influenza
infect
exclud
limit
generaliz
decreas
potenti
confound
durat
symptom
prior
initi
present
avail
earli
studi
analysi
avail
data
time
present
sensit
analysi
show
although
longer
time
symptom
onset
picu
admiss
associ
increas
fatal
unlik
explain
associ
vancomycin
monotherapi
death
collect
data
antimicrobialrel
advers
event
would
difficult
given
high
rate
multiorgan
failur
picu
admiss
mrsacoinfect
children
import
note
mrsa
coinfect
occur
virus
focu
influenza
viru
infect
could
determin
clinic
cours
outcom
mrsa
coinfect
noninfluenza
viral
infect
similar
although
limit
realworld
evid
antibiot
efficaci
pediatr
coinfect
sporad
fulmin
diseas
high
fatal
indic
vancomycin
alon
insuffici
therapi
children
picu
acut
respiratori
failur
result
diagnost
test
mrsa
influenza
delay
hour
empir
therapi
may
need
optim
clinic
outcom
older
age
prior
good
health
well
leukopenia
shock
requir
vasopressor
support
present
associ
mrsa
coinfect
thu
patient
present
acut
respiratori
distress
similar
featur
influenza
season
prompt
consider
addit
antimrsa
antibiot
diagnost
studi
pend
although
addit
clindamycin
vancomycin
appear
prudent
case
high
clinic
suspicion
coinfect
clindamycin
resist
must
monitor
nation
ongo
registri
fatal
pediatr
coinfect
antimicrobi
suscept
antibiot
manag
collect
clinic
sampl
could
help
guid
care
addit
adjunct
therapi
antibodi
target
aureu
toxin
may
decreas
mortal
children
mrsa
coinfect
